Pharma DECODED
Previous edition: 16 May 2024
Share article
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Takeda's dengue vaccine obtains WHO prequalification
The TAK-003 vaccine targets all four virus serotypes.
Takeda's new dengue vaccine, TAK-003, has received prequalification from the World Health Organization (WHO).
TAK-003 is the second dengue vaccine to achieve this status.
WHO has recommended the use of the new vaccine for children aged six to 16 years in areas with a high burden of dengue and transmission.
A live-attenuated vaccine, TAK-003 includes weakened forms of all four serotypes of the dengue virus.
It is designed to be administered in a two-dose regimen with an interval of three months between doses.
Sanofi Pasteur’s CYD-TDV dengue vaccine had previously received the WHO prequalification.
Dengue, a mosquito-borne disease, poses a significant health threat with an estimated 100 to 400 million cases annually.
The disease is prevalent in Asia, Africa and the Americas, with the WHO region of the Americas reporting 4.5 million cases and 2,300 deaths in 2023 alone.
WHO regulation and prequalification director Dr Rogerio Gaspar stated: “The prequalification of TAK-003 is an important step in the expansion of global access to dengue vaccines, as it is now eligible for procurement by UN agencies including UNICEF and PAHO.
“With only two dengue vaccines to date prequalified, we look forward to more vaccine developers coming forward for assessment so that we can ensure vaccines reach all communities who need it.”
Earlier this month, Takeda entered an exclusive worldwide option and licence agreement with AC Immune for an Alzheimer's disease immunotherapy in a $2.2bn deal.
Latest news
KRAS inhibitors: The next frontier beckons
There has been several developments in the KRAS inhibitor space, shaping the KRAS inhibitors of the future.
FDA approves Bristol Myers Squibb's Breyanzi for follicular lymphoma
The approval is based on results from the open-label, global, multi-centre, single-arm Phase II TRANSCEND FL clinical trial.
FDA rejects label expansion for Dynavax's hepatitis B vaccine
The US agency rejected the expanded use of Dynavax’s vaccine for adults on haemodialysis, citing insufficient efficacy and safety data.
Tracking the opioid lawsuit settlements amidst calls for oversight
The US National Opioid Settlement is distributing more than $54 billion to communities grappling with the opioid crisis.
Vanda Pharmaceuticals reports positive data from motion sickness trial
In the trial, only 10.4% and 18.3% of the subjects reported vomiting on the 170mg and 85mg doses, respectively.
Moleculin begins NIH-funded Phase II glioblastoma treatment trial
The primary goal of the study is to measure progression-free survival.
Allucent receives grant for decentralised Covid-19 vaccine trial
The company received the award to conduct a trial assessing correlates of protection following Covid-19 vaccination.
In our previous edition
Pharma Decoded
Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised
15 May 2024
Pharma Decoded
Sanofi to make €1bn biomanufacturing investment in France
14 May 2024
Pharma Decoded
RAPT terminates Phase II trials for lead candidate following clinical hold
13 May 2024
Newsletters in other sectors
Aerospace, Defence & Security
Automotive
Banking & Payments
Medical Devices
Oil & Gas
Travel and Tourism
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer